Why are young people getting cancer? a massive study aims to find out.
NCT ID NCT04955808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in different racial and ethnic groups. Participants provide samples during surgery, and no direct treatment is given.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2017
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients undergoing surgery to remove tumor tissue
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with either: * Histologically confirmed invasive carcinoma or multiple myeloma OR * Clinical diagnosis of carcinoma or multiple myeloma OR * Suspected clinical diagnosis of multiple myeloma * Patients with one of following tumor types and age ranges: * Breast cancer diagnosis at ages 18-45 * Colon cancer diagnosis at ages 18-55 * Kidney cancer at diagnosis at ages 18-50 (American Indian or Alaska Native \[AIAN\] and non-Hispanic Whites \[NHW\] only) * Liver cancer diagnosis at ages 18-55 * Prostate cancer diagnosis at ages 18-55 * Multiple myeloma diagnosis at ages 18-50 * Patients whose tumor specimen was collected or will be collected during one of the following routine procedures: * Surgery to remove cancer OR * Routine biopsy procedures performed to confirm a histologic diagnosis OR * Routine biopsy procedure performed to obtain additional tumor material for routine prognostic or predictive biomarkers OR * Routine procedure to place a vascular access device prior for systemic therapy * Patients who have received no therapy for their cancer other than surgery, irrespective of stage * Collection of specimens from living patients: * Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol * Collection of specimens from deceased patients: * Banked tissue samples and/or banked biologic fluid specimens of deceased patients may be used as long as all samples or specimens are properly de- identified prior to submission * Sites must use the Central Institutional Review Board for the National Cancer Institute (NCI CIRB). Exclusion Criteria: * Patients who do not meet criteria for an early onset malignancy * Prior systemic therapy or radiation therapy for their malignancy * Tumor does not meet quality metrics * Patient refused consent for use of tissue for research activities included in the Early Onset Malignancies Initiative * A diagnosis of a synchronous invasive malignancy * Patients with a history of invasive cancer or hematologic malignancy in preceding 5 years
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Cancer Institute Division of Cancer Prevention
Rockville, Maryland, 20850, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bispecific antibody combo aims to deepen myeloma responses
- Can a stronger drug cocktail give older myeloma patients a better start?
- Green dye vs blue dye: which finds Cancer-Linked lymph nodes better?
- Cheap blood count ratios eyed as window into Myeloma's inflammatory grip
- Can a t-cell engager rescue myeloma that outsmarted CAR-T?
- Can myeloma treatment work without steroids?